These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23955273)

  • 1. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
    Clozel T; Yang S; Elstrom RL; Tam W; Martin P; Kormaksson M; Banerjee S; Vasanthakumar A; Culjkovic B; Scott DW; Wyman S; Leser M; Shaknovich R; Chadburn A; Tabbo F; Godley LA; Gascoyne RD; Borden KL; Inghirami G; Leonard JP; Melnick A; Cerchietti L
    Cancer Discov; 2013 Sep; 3(9):1002-19. PubMed ID: 23955273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.
    Steinhardt JJ; Gartenhaus RB
    Cancer Discov; 2013 Sep; 3(9):968-70. PubMed ID: 24019329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
    Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
    Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics: Showing a more sensitive side.
    McCarthy N
    Nat Rev Cancer; 2013 Oct; 13(10):680. PubMed ID: 24030504
    [No Abstract]   [Full Text] [Related]  

  • 5. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
    Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Martin P; Bartlett NL; Chavez JC; Reagan JL; Smith SM; LaCasce AS; Jones J; Drew J; Wu C; Mulvey E; Revuelta MV; Cerchietti L; Leonard JP
    Blood; 2022 Feb; 139(8):1147-1159. PubMed ID: 34428285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
    Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
    Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
    Wang W; Wang J; Li Z; Zhu M; Zhang Z; Wang Y; Jing H
    Oncol Rep; 2016 Jan; 35(1):139-46. PubMed ID: 26498513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
    Wang W; Wang J; Li M; Ying J; Jing H
    Int J Mol Med; 2015 Sep; 36(3):698-704. PubMed ID: 26133246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
    Fan H; Lu X; Wang X; Liu Y; Guo B; Zhang Y; Zhang W; Nie J; Feng K; Chen M; Zhang Y; Wang Y; Shi F; Fu X; Zhu H; Han W
    J Immunol Res; 2014; 2014():371087. PubMed ID: 24963497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
    El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
    Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
    Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
    Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
    Gao D; Herman JG; Guo M
    Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
    Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
    Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
    Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
    Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation.
    Liu J; Min S; Kim D; Park J; Park E; Koh Y; Shin DY; Kim TK; Byun JM; Yoon SS; Hong J
    Clin Epigenetics; 2023 May; 15(1):75. PubMed ID: 37138342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
    Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.